key: cord-0333644-l960q9an
authors: Tallmadge, R. L.; Laverack, M. A.; Cronk, B.; Venugopalana, R.; Martins, M.; Zhang, X.; Elvinger, F.; Plocharczyk, E.; Diel, D.
title: Viral load and infectivity of SARS-CoV-2 in paired respiratory and oral specimens from symptomatic, asymptomatic or post-symptomatic individuals
date: 2021-11-14
journal: nan
DOI: 10.1101/2021.11.13.21266305
sha: 5b714ff39aacf99a435465348b76cafe54fc8258
doc_id: 333644
cord_uid: l960q9an

In the present study, we assessed the diagnostic sensitivity and determined the viral load and infectivity of SARS-CoV-2 in paired respiratory (nasopharyngeal and anterior nares) and oral samples (saliva and sublingual swab). Samples were collected from 77 individuals of which 75 were diagnosed with COVID-19 and classified as symptomatic (n=29), asymptomatic (n=31), or post-symptomatic (n=15). Specimens were collected at one time point from each individual, between day 1 to 23 after the initial COVID-19 diagnosis, and included self-collected saliva (S), or sublingual (SL) swab, and bilateral anterior nares (AN) swab, followed by healthcare provider collected nasopharyngeal (NP) swab. Sixty-three specimen sets were tested using five assay/platforms. The diagnostic sensitivity of each assay/platform and specimen type was determined. Of the 63 specimen sets, SARS-CoV-2 was detected in 62 NP specimens, 52 AN specimens, 59 saliva specimens, and 31 SL specimens by at least one platform. Infectious SARS-CoV-2 was isolated from 21 NP, 13 AN, 12 saliva, and one SL specimen out of 50 specimen sets. SARS-CoV-2 isolation was most successful up to 5 days after initial COVID-19 diagnosis using NP specimens from symptomatic patients (16 of 24 positives, 66.67%), followed by specimens from asymptomatic patients (5 of 17 positives, 29.41%), while it was not very successful with specimens from post-symptomatic patients. Benefits of self-collected saliva and AN specimens balance the loss of sensitivity relative to NP specimens. Therefore, saliva and AN specimens are acceptable alternatives for symptomatic SARS-CoV-2 diagnostic testing or surveillance with increased sampling frequency of asymptomatic individuals.

with phosphate buffered saline (PBS) (Corning ® ) and inoculated with 150 µl of each sample and 169 inoculum adsorbed for 1 h at 37 °C with 5% CO 2 . Mock-inoculated cells were used as negative 170 controls. After adsorption, replacement cell culture media (Dulbecco's modified eagle medium 171 (DMEM) supplemented with 10% fetal bovine serum (FBS), l-glutamine (2 mM), penicillin 172 (100 U·ml −1 ), streptomycin (100 μ g·ml −1 ), and gentamicin (50 μ g·ml −1 )) was added and cells 173 were incubated at 37 °C with 5% CO 2 and monitored daily for cytopathic effect (CPE) for 3 174 days. Cell cultures with no CPE were frozen, thawed, and subjected to two additional blind 175 passages/inoculations in Vero E6/TMPRSS2 cell cultures. CPE positive wells and wells with no 176 CPE at the end of the third passage, were subjected to immunofluorescence staining using 177 SARS-CoV-2 N-specific mAbs as previously described (18). CoV-2 assays was evaluated on multiple specimen sets (NP, AN, S, and SL) collected from 77 187 patients. Specimens were obtained in duplicate from 75 patients that had previously tested 188 positive for SARS-CoV-2 and from two patients with previous negative SARS-CoV-2 test 189 results (Fig. 1) . Of the 75 specimen sets collected from patients diagnosed with 68 190 sets were tested on all 5 platforms under evaluation: Rheonix, the EZ-SARS-CoV-2 assay on two 191 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 real-time RT-PCR detection systems (ABI 7500 and QuantStudio 5), and the TaqPath 19 Combo kit on the same two real-time RT-PCR detection systems (ABI 7500 and QuantStudio 193 5) . SARS-CoV-2 was detected by at least one assay/platform in 63 of the 68 sample sets. The 194 five sample sets in which SARS-CoV-2 was not detected were excluded from further analyses as 195 shown in Fig. 1 . Virus isolation was performed on 50 of the 63 paired specimen sets. This 196 experimental design allowed comparison of the diagnostic sensitivity among all specimen types 197 and detection assays. 198 To facilitate the interpretation of the results in the context of SARS-CoV-2 infection 199 dynamics, the 63 patients included in our study were further categorized as symptomatic, 200 asymptomatic, or post-symptomatic following the criteria described in the Materials and 201

Methods. The SARS-CoV-2 RT-PCR results obtained from the four specimen types tested across 202 the three assays and platforms under evaluation are shown for 25 symptomatic patients (Table  203 1), 24 asymptomatic patients ( Table 2) , and 14 post-symptomatic patients ( Table 3) . These 204 individuals had their initial diagnostic test performed 1-23 days before the multipls specimen set 205 was collected for this study. 206

Clinical performance of molecular SARS-CoV-2 assays. The diagnostic sensitivity of each 207 specimen was evaluated across the different assays and detection platforms used in our study. 208

The diagnostic sensitivity of each assay performed with specimens from 25 symptomatic patients 209 is presented in Table 4 . These specimens were collected between 2 and 5 days after the initial 210 diagnostic test (mean of 3.42 days) and SARS-CoV-2 was detected in 96% of NP specimens on 211 the Rheonix platform and in 100% of NP specimens with the EZ-SARS-CoV-2 or TaqPath 212 COVID-19 real-time RT-PCR assays. SARS-CoV-2 was detected in 92 to 96% of AN and saliva 213 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 specimens from symptomatic patients across all platforms. In contrast, SARS-CoV-2 detection 214 was markedly lower in SL specimens, ranging from 40 to 60% across platforms. 215 SARS-CoV-2 was detected by all assays and platforms in all 4 specimens from 7 of the 216 25 symptomatic patients. In 16 of the 25 symptomatic patients, SARS-CoV-2 was detected in 217 NP, AN, and saliva specimens by all assays and platforms, whereas detection in SL specimens 218 was less reliable. The remaining 2 sets of specimens were collected 3 days after the initial 219 diagnosis, and SARS-CoV-2 was detected most consistently using NP from these patients. 220

The sensitivity of the assays was lower in asymptomatic patients ( Table 5 ) than in 221 symptomatic patients even though they were collected within the same time frame of 1 to 5 days 222 after the initial diagnostic test (mean 3.41 days). Using NP specimens, the Rheonix platform 223 detected 96% of asymptomatic patients, while EZ-SARS-CoV-2 and TaqPath COVID-19 real-224 time RT-PCR assays detected 92%. Detection of SARS-CoV-2 in AN specimens decreased to 225 79% on the Rheonix and ranged from 88 to 92% across EZ-SARS-CoV-2 and TaqPath COVID-226 19 real-time RT-PCR assays and platforms. The Rheonix platform presented the higher 227 sensitivity with asymptomatic saliva specimens than AN (83%), whereas the sensitivity of the 228 TaqPath COVID-19 assay dropped to 75%. The EZ-SARS-CoV-2 assay detected nearly 92% of 229 saliva specimens on the ABI 7500 Fast platform, but only 83% on the QuantStudio 5 platform. 230

Detection of SARS-CoV-2 in SL specimens was lower on all platforms, ranging from 25 to 42%. 231 SARS-CoV-2 was detected in all specimen types from 4 of the 24 asymptomatic patients 232 by all assays and platforms. Thirteen pairs of NP, AN, and saliva specimens from asymptomatic 233 patients were detected by all assays and platforms. For some asymptomatic samples, the rate of 234 SARS-CoV-2 detection was very low, even if they were collected 2 days after diagnosis (Table  235 2). 236 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Diagnostic sensitivity of these SARS-CoV-2 assays using specimens from a cohort of 237 post-symptomatic patients were lower than the symptomatic or asymptomatic patients (Table 6) , 238 with sample collection performed 8.46 days after initial diagnostic test on average (range 4 to 23 239 days). The Rheonix and EZ-SARS-CoV-2 assay on the ABI 7500 Fast platform detected nearly 240 86% of post-symptomatic NP specimens, although the other real-time PCR assays and platforms 241 detected only 57 to 79% of NP specimens. Only approximately 36 to 43% of AN specimens 242 were detected across the platforms. The EZ-SARS-CoV-2 assay was able to detect 57% of saliva 243 specimens on the ABI 7500 Fast platform and 50% on the QuantStudio 5 platform; however, 244 only approximately 36% were detected by the Rheonix and TaqPath COVID-19 assays. SARS-245

CoV-2 was only detected in 7 to 14% of post-symptomatic SL specimens. 246 SARS-CoV-2 was not detected in any complete set of paired specimens from post-247 symptomatic patients (Table 3) . SARS-CoV-2 was detected in NP specimens across all 248 platforms from 8 of 14 post-symptomatic patients. All assays and platforms detected SARS-249

CoV-2 in 4 AN specimens, 3 saliva specimens, and 1 SL specimen collected from post-250 symptomatic patients. 251

Considering all SARS-CoV-2-positive specimen sets regardless of symptoms, the 252 Rheonix and EZ-SARS-CoV-2 assay performed on the ABI 7500 Fast platform detected 253 approximately 94% of NP specimens ( Table 7) . The TaqPath COVID-19 assay detected 92% of 254 NP specimens on the ABI 7500 Fast platform; on the QuantStudio 5 platform approximately 87 255 to 89% of NP specimens were detected by either real-time RT-PCR assay. Detection of AN 256 specimens ranged from approximately 75 to nearly 81% across platforms. The EZ-SARS-CoV-2 257 assay was able to detect approximately 86% of saliva specimens on the ABI 7500 Fast platform 258 and 79% on the QuantStudio 5 platform. The Rheonix platform detected approximately 78% of 259 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint saliva specimens overall. The TaqPath COVID-19 assay detected 73% of saliva specimens, 260 regardless of platform. At most, 41% of SL specimens were detected by the EZ-SARS-CoV-2 261 assay on the ABI 7500 Fast platform, and detection decreased to a low of 27% on the Rheonix 262 platform ( Table 7) . 263

The overall agreement between the 5 platforms evaluated was compiled for each 264 specimen type, considering all 63 paired specimen sets ( Table 8) . SARS-CoV-2 detection was 265 highest using NP specimens across platforms at 87.30%, followed by 82.54% of AN specimens, 266 and 74.60% of saliva specimens. SARS-CoV-2 detection decreased to 61.9% in SL specimens 267 across platforms. 268

Detection of SARS-CoV-2 RNA was most successful from NP specimens and so the 269 percent detection relative to NP was determined for the remaining specimen types across 270 platforms ( Table 9) . SARS-CoV-2 was detected from 79-90% of AN and saliva specimens 271 relative to NP. However, 95% of saliva specimens were detected relative to NP when detection 272 from all platforms were combined in contrast to 84% of AN specimens; this was largely due to 273 positive saliva specimens collected from post-symptomatic patients ( Table 3) . Relative to NP 274 specimens, SL specimens yielded 52% detection when results from all platforms were combined. 275

To further investigate the differences between specimen types, we compared the SARS-277

CoV-2 cycle threshold (Ct) value detected by the EZ-SARS-CoV-2 assay on the ABI 7500 Fast 278 platform. Of the total 63 specimen sets, SARS-CoV-2 was detected in 59 NP specimens, 51 AN 279 specimens, 54 saliva specimens, and 26 SL specimens (Fig. 2) . The median Ct value in NP 280 specimens was 26.13, the median Ct value detected in AN specimens was 26.19, and the median 281

Ct value was 26.26 in saliva specimens. There was no difference between Ct values obtained 282 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 from NP, AN, or saliva specimens (p≥0.1681). However, the median SARS-CoV-2 Ct value 283 detected in SL specimens was zero, which indicated the lack of SARS-CoV-2 detection. SARS-284

CoV-2 Ct values were detected in 26 of the 63 SL specimens and in general they tend to be 285 higher than those detected in other specimen types. SARS-CoV-2 Ct values obtained from SL 286 specimens were different from NP, AN, and saliva specimen Ct values (p<0.0030). 287 SARS-CoV-2 Ct values detected by the EZ-SARS-CoV-2 assay on the ABI 7500 Fast 288 platform were also compared between symptomatic, asymptomatic, and post-symptomatic 289 groups. No difference was found between symptomatic and asymptomatic groups for Ct values 290 detected from NP (p=0.2307), AN (p=0.0778), saliva (p=0.2602) or SL (p=0.8490) specimens. 291

When Ct values determined from specimens collected from post-symptomatic patients were 292 compared to those of symptomatic or asymptomatic patients, the Ct values in the post-293 symptomatic group were higher for NP (p<0.0003) and saliva (p<0.0036) specimens. The 294 difference in Ct values from post-symptomatic AN specimens neared significance when 295 compared to symptomatic AN specimens (p=0.0581) but did not differ from asymptomatic AN 296 specimens (p=0.7547). There were not enough Ct values from post-symptomatic SL specimens 297 for statistical comparison. 298

To appreciate the dynamics of SARS-CoV-2 Ct values within a patient, only specimen 299 sets with a Ct value for all 4 specimens from the EZ-SARS-CoV-2 assay on the ABI 7500 Fast 300 platform were plotted (Fig. 3) . From these 24 specimen sets, NP samples presented the lowest Ct 301 values followed by AN (p=0.0014), S (p=0.0194), and SL (p<0.0001) samples. The latter 302 presented the highest Ct value of all four specimen types (p<0.0001, Fig. 3) . 303

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint SARS-CoV-2 isolation was performed on 50 sets of specimens. The virus was isolated 305 from 21 of 50 NP, 13 of 50 AN, 12 of 50 saliva, and one SL specimen (Fig. 4) . SARS-CoV-2 306 isolation was most successful using specimens from symptomatic patients and isolation was not 307 successful in specimens from post-symptomatic patients (Fig.5 ). Stratifying successful virus 308 isolation by specimen type, NP was the specimen with the highest isolation rate, with virus 309 isolated from 16 of 24 symptomatic and 5 of 17 asymptomatic specimens (Fig.5A, 5B) . AN was 310 the next most successful specimen type with virus isolated from 10 of 24 symptomatic and 3 of 311 17 asymptomatic specimens ( Specimens that yielded infectious SARS-CoV-2 had significantly lower Ct values for 318 symptomatic NP (p=0.0007), AN (p<0.0001), and saliva (p=0.0009) specimens than specimens 319 that did not yield infectious virus (Fig.5A ). Lower SARS-CoV-2 Ct values (p≤0.0324) were also 320 detected in asymptomatic specimens that yielded infectious virus in comparison to specimens 321 that did not yield virus (Fig.5B) . 322

The success of recovery of infectious SARS-CoV-2 decreased over time, with virus being 323 recovered from 100% of the samples from symptomatic patients collected 2 days after initial 324 diagnosis, which declined to 50% of the samples by 5 days (Fig.5A ). Virus isolation was less 325 successful from asymptomatic patient specimens, even when collected 1 day after diagnosis, 326

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint although it was possible to recover SARS-CoV-2 virus from asymptomatic specimens collected 327 up to 5 days following diagnosis (Fig.5B) . 328

Discussion 330

This study was undertaken to compare the performance of five molecular SARS-CoV-2 331 assay/platform combinations across paired respiratory (NP and AN swabs) and oral (S and SL 332 swab) specimens collected from symptomatic, asymptomatic, and post-symptomatic patients. All 333 five assay/platform combinations assessed in this study are based on RT-PCR. The Rheonix 334

MDx assay incorporates cell lysis, RNA purification, amplification, and detection steps in a 335 closed system. For the real-time RT-PCR assays, nucleic acid isolation was performed separate 336 from amplification, although the same elution was used for all real-time assays. The limit of 337 detection (LoD) of these assays is similar despite the differences in methodology: the Rheonix 338

LoD is 625 genomic equivalents per mL, the EZ-SARS-CoV-2 assay LoD is 250 genome 339 equivalents per mL and the TaqPath COVID-19 assay LoD is 10 genomic equivalents per 340 reaction or 500 genome equivalents per mL (17, The comparative diagnostic sensitivity values determined herein revealed that the EZ-344 SARS-CoV-2 assay on the ABI 7500 platform was the most sensitive assay/platform 345 combination. The Rheonix platform followed closely and demonstrated equivalent performance 346 on NP specimens. The TaqPath COVID-19 assay on the ABI 7500 platform ranked third in 347 performance. The QuantStudio 5 platform provided lower sensitivity, with the EZ-SARS-CoV-2 348 assay performing slightly better than the TaqPath COVID-19 assay. 349 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10. 1101 /2021 Collection of 4 specimens from each patient allowed for direct comparisons of detection 350 between specimens. NP specimens provided the best rate of detection among specimens 351 collected from symptomatic and asymptomatic patients across the platforms used herein, with 352 detection rates of 92 to 100%. NP has been described as the most sensitive specimen in other 353 studies, even if 100% detection is not achieved (19, 20) . This can likely be explained by the fact 354 that SARS-CoV-2 replicates in nasal turbinates and the NP swab collection procedure harvests 355 infected turbinate epithelial cells (18, 21) . Detection rates of SARS-CoV-2 from AN and saliva 356 specimens were slightly lower at 92-96% for symptomatic patients, with equivalent performance 357 across the real-time RT-PCR platforms. However, AN and saliva specimens provided lower 358 sensitivity when collected from asymptomatic patients (75 to 92%). A meta-analysis of 359 published data also found a reduced detection rate from nasal swabs (AN or mid-turbinate) and 360 saliva when compared to NP swabs collected from the same patient (20). This again, could be a 361 result of the virus tropism and slight differences in viral loads at different replication sites (e.g. 362 nasal turbinate epithelium vs tonsil). SARS-CoV-2 detection from sublingual swab specimens 363 was inferior to the other specimens in this study, with detection rates of 40-60% from 364 symptomatic patient specimens and 25 to 42% from asymptomatic patient specimens. 365

There was only one set of specimens collected from an asymptomatic individual (patient 366 33, Table 2 ) for which SARS-CoV-2 was not detected in NP on any platform; only saliva and 367 sublingual swab specimens were positive and only when using the EZ-SARS-CoV-2 assay on 368 the ABI 7500 platform. Detection of SARS-CoV-2 in saliva samples but not in NP has been 369 reported for some patients across multiple studies (22-29). Senok and colleagues found that 370 saliva specimens were especially sensitive in asymptomatic patients (30). It should be noted that 371 the performance of saliva specimens for SARS-CoV-2 diagnosis differs according to saliva 372 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint collection and processing methods (20, 23, 31). As expected and reported in the literature neither 373 NP, nor AN or saliva specimens provide 100% sensitivity (32, 33) . Some studies suggest that 374 discordant results between paired specimens could be due to the distribution of viral replication 375 specific to that individual (23). Additionally, the dynamics of virus infection and differences in 376 viral load over time are also important factors that affect diagnostic sensitivity. 377

A strength of this study is the inclusion of symptomatic, asymptomatic, and post-378 symptomatic patients, allowing comparison of detection rates between these groups. The rate of 379 detection of SARS-CoV-2 was highest using specimens from symptomatic patients (92 to 100% 380 for NP, AN and saliva), followed by asymptomatic patient specimens (75 to 96% for NP, AN 381 and saliva). Although detection using NP collected from post-symptomatic patients was 86% on 382 the two most sensitive platforms, the other specimens did not robustly detect SARS-CoV-2 in 383 post-symptomatic patients. 384

Equivalent SARS-CoV-2 Ct values were obtained from NP, AN, and saliva specimens 385 when results from all 63 sets were analyzed. Comparable SARS-CoV-2 Ct values from NP and 386 saliva specimens have also been found in other studies (27, 29, (34) (35) (36) (37) . Further, no difference 387 was found when SARS-CoV-2 Ct values were compared between specimens collected from 388 symptomatic and asymptomatic patients, consistent with other findings based on Ct values (38) 389 and viral load (39). However, Ct values obtained from post-symptomatic patients NP and saliva 390 specimens were higher than Ct values from symptomatic or asymptomatic specimens, likely 391 reflecting a decrease in viral load after the resolution of symptoms and the infection. When the 392 dataset was narrowed to 24 individuals for which each specimen was positive, differences in 393 SARS-CoV-2 Ct values between specimens were observed. In this case, the SARS-CoV-2 Ct 394 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10. 1101 /2021 values detected from NP specimens were lower than those from AN and S, and the Ct values 395 detected from SL specimens were higher than NP, AN, or S. 396 SARS-CoV-2 isolation was attempted with 50 of 63 positive sample sets and this enabled 397 additional insights into virus infectivity among specimen types over time. Overall, SARS-CoV-2 398 isolation was successful in 23.5% of specimens tested. Infectious virus was isolated 399 predominantly in specimens from symptomatic patients (16 of 25 [64%]). In contrast, infectious 400 virus was isolated from less than one-third of specimens collected from asymptomatic patients ( shedding beyond the detection of infectious virus confounds establishing guidelines for releasing 416 individuals from isolation (47, 48) . It is possible that intact viral genomes and "live" particles are 417 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint present and shed, however, the viral load might be too low for successful virus isolation late in 418 the course of infection (40, 41, 46) . 419

Collectively, this work identified the EZ-SARS-CoV-2 assay on the ABI 7500 platform 420 as the most sensitive SARS-CoV-2 test across patients segregated by symptomology and across 421 specimen types. The Rheonix system also demonstrated high diagnostic sensitivity on NP, AN, 422 and saliva specimens. Although NP specimens provided the highest sensitivity, 86-90% of paired 423 AN and saliva specimens were detected. As AN and saliva specimens can be self-collected with 424 minimal PPE, materials, and assistance, they offer alternatives to NP specimens. The robust 425 detection of SARS-CoV-2 from AN and saliva specimens by the EZ-SARS-CoV-2 assay 426 supports the use of either specimen in a surveillance program of asymptomatic individuals. 427 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10. 1101 /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.13.21266305 doi: medRxiv preprint shown on the y-axis. Days 783 between initial diagnostic test 784 and specimen collection for this 785 study are on the x-axis. 786

Successful virus isolation 787

(filled/black symbols) or lack of 788

virus isolation (open symbols) is 789 on -. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

A Novel Coronavirus from 435 Patients with Pneumonia in China

Early Transmission Dynamics in Wuhan, China, of 441 Novel Coronavirus-Infected Pneumonia

Nowcasting and forecasting the potential domestic 443 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 444 modelling study

599 The early phase of the COVID-19 outbreak in

Culture-based virus isolation to evaluate 602 potential infectivity of clinical specimens tested for COVID-19

Virological assessment of hospitalized 606 patients with COVID-2019

Viral cultures for COVID-19 608 infectious potential assessment -a systematic review

Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from 612 COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells

Duration of Viral Shedding of Discharged Patients 615 With Severe COVID-19

Clinical and virologic 640 characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the 641 United States

SARS-CoV-2 virus 644 culture and subgenomic RNA for respiratory specimens from patients with mild 645 Coronavirus disease

Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly 648 Symptomatic Patients with COVID-19 in a Later Phase

Necessity for detection of SARS-651

CoV-2 RNA in multiple types of specimens for the discharge of the patients with COVID-652 19